Catalysts / CGON
Upcoming FDA decisions and readouts we track for CG Oncology, each with the filing that announced it.
FreeBioList tracks 2 upcoming catalysts for CG Oncology (CGON, listed on Nasdaq). Both concern Cretostimogene grenadenorepvec (High-risk BCG-unresponsive NMIBC; Intermediate-risk non-muscle invasive bladder cancer).
First on the list: the Regulatory submission for Cretostimogene grenadenorepvec (High-risk BCG-unresponsive NMIBC), guided by the company to Q4 2026. By stage, the upcoming rows are 1 Phase 3 readout and 1 Regulatory submission.
Both rows link to SEC filings (8-K or 6-K). 1 has been verified by a person reading the filing itself, most recently on 12 Sep 2026. 1 is flagged needs check; open the row to read why. The methodology page explains each status.
Background reading: NDA vs BLA: the two kinds of US drug application; How to read a Phase 3 topline readout.
| Company ▾ | Drug ▾ | Effect / indication | Next catalyst ▾ | Phase / type ▾ | Status ▾ | Source | Options |
|---|---|---|---|---|---|---|---|
| CG Oncology CGON · Nasdaq | Cretostimogene grenadenorepvec | High-risk BCG-unresponsive NMIBC | Q4 2026 company guidance |
Regulatory submission | Verified | 8-K exhibit 99.1 ↗ | Yes |
| CG Oncology CGON · Nasdaq | Cretostimogene grenadenorepvec | Intermediate-risk non-muscle invasive bladder cancer | 2026 timing unconfirmed |
Phase 3 readout | Needs check | 8-K exhibit 99.1 ↗ | Yes |
FreeBioList